Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Jazz Pharmaceuticals excels in Q3 with record sales and growth

Jazz Pharmaceuticals' Q3 2024 performance reflects strong revenue growth and operational resilience, driven by key products and ongoing innovation efforts.
While facing challenges like revenue impact for Rylaze, the company remains focused on normalizing demand and advancing its pipeline programs.
With a solid financial foundation and a strategic focus on high-potential areas, Jazz Pharmaceuticals is well-positioned to capitalize on growth opportunities.
By affirming revenue guidance, investing in innovation, and exploring business development prospects, Jazz Pharmaceuticals demonstrates a commitment to long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Focus on commercial execution drove 1Q23 total revenues of $892.8 million Continued adoption of Xywav ® ; net product sales increased 49% 1Q23 compared to 1Q22 Confident in blockbuster potential of Epidiolex ® ; net product sales increased 20% 1Q23 compared to 1Q22 Strong Rylaze ®  demand drove 58% increase in net product sales 1Q23 compared to 1Q22 Enhanced pipeline positioned to deliver at least three late-stage data readouts by the end of 2024 DUBLIN , May 10, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2023, affirmed 2023 financial guidance and provided business updates. "This quarter, we once again delivered strong commercial results, advanced our efforts to unlock the tremendous potential of our pipeline and built on our record of driving operational excellence.

Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance

DUBLIN , May 2, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 2023 RBC Capital Markets Global Healthcare Conference. Company management will participate in a fireside chat on Tuesday, May 16, 2023, at 4:05 p.m.

Jazz Pharmaceuticals to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

Data from multiple studies of investigational bispecific drug zanidatamab, including pivotal Phase 2 biliary tract cancers (BTC) trial results, demonstrate breakthrough HER2-targeted pan-tumor potential Nine abstracts accepted for presentation, including two oral presentations, reinforce Jazz's growing leadership in oncology and commitment to patients through clinically beneficial treatments and novel research Company to host investor webcast on June 2, 2023, to review zanidatamab BTC data presentation DUBLIN , April 27, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present nine abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Presentations include clinical data from trials of zanidatamab, Zepzelca® (lurbinectedin) and Vyxeos® (daunorubicin and cytarabine).

Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023

DUBLIN , April 26, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 first quarter financial results on Wednesday, May 10, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

Jazz Pharmaceuticals to Report 2023 First Quarter Financial Results on May 10, 2023

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Eleven abstracts emphasize Jazz's leadership in neuroscience and commitment to advance understanding of sleep disorders, epilepsy and movement disorders Three oral presentations share meaningful data results in idiopathic hypersomnia and essential tremor DUBLIN , April 19, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston. "Our presence at the 2023 AAN Annual Meeting further reflects Jazz's scientific leadership in developing therapies for debilitating sleep disorders and rare epilepsy syndromes that advance treatment for people living with these conditions," said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting

Innovative Industrial Properties

Scotts Miracle-Gro

Are Pot Stocks On Your List For April? The post Top Pot Stocks For Long Term Investing? 3 To Watch In April appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Top Pot Stocks For Long Term Investing? 3 To Watch In April

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Jazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?

Support to include dedicated educational website, science advisory panel, patient video series and strategic alliance across sleep patient advocacy organizations Research shows that sleep disorders are associated with increased risks of cardiovascular comorbidities, including those with narcolepsy being two- to three-times more likely to have a stroke or heart attack than people without narcolepsy DUBLIN , March 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced an expansion of its support of the American Heart Association (Association) to provide the sleep disorder community an in-depth understanding of the cardiovascular risks associated with these debilitating disorders. Through this initiative, the Association aims to help people living with sleep disorders determine when professional help may be appropriate and healthcare professionals recognize ways to improve heart health for the patients they treat.

Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health

Aurora Cannabis

Canopy Growth

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

HEXO Corp

High Tide

OrganiGram Holdings Inc.

SNDL Inc.

Trulieve Cannabis Corp.

This developing industry has ample opportunity and sustained tailwinds. Very few U.S. companies have positive operating margins; very few of their Canadian counterparts have positive gross margins.

Finding The Long-Term Winners In The Cannabis Sector

Jazz Pharmaceuticals doesn't face many of the challenges other cannabis companies have to deal with. The company's current lineup and pipeline programs paint a bright picture for its future.

My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years

DUBLIN, March 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023. Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca® (lurbinectedin), zanidatamab and JZP898.

Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline

Village Farms International

Get in the know about medical marijuana stocks.

Best Medical Marijuana Stocks to Buy

ACI Worldwide

Axos Financial Inc.

Crestwood Equity Partners

Churchill Downs

Nexstar Media Group

Performance Food Group

Valvoline

The best mid-cap stocks are the market's so-called "sweet spot," offering up an ideal combination of financial stability and growth potential.

Best Mid-Cap Stocks to Buy Now

Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.

Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales

Jazz Pharmaceuticals plc (NASDAQ:JAZZ ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Darren Fox - Executive Director of Investor Relations Bruce Cozadd - Chairman and Chief Executive Officer Dan Swisher - President and Chief Operating Officer Rob Iannone - Executive Vice President, Global Head of R&D Renee Gala - Executive Vice President and Chief Financial Officer Kim Sablich - Executive Vice President and General Manager, United States Conference Call Participants Jessica Fye - J.P. Morgan Marc Goodman - SVB Leerink Jason Gerberry - Bank of America Annabel Samimy - Stifel David Amsellem - Piper Sandler Gary Nachman - BMO Balaji Prasad - Barclays Gregory Renza - RBC Brandon Folkes - Cantor Fitzgerald Ash Verma - UBS Ami Fadia - Needham & Company Omari Baruti - Goldman Sachs Greg Fraser - Truist Operator Good day, and welcome to the Jazz Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Call.

Jazz Pharmaceuticals plc (JAZZ) Q4 2022 Earnings Call Transcript

Jazz (JAZZ) delivered earnings and revenue surprises of -113.73% and 0.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Reports Q4 Loss, Misses Revenue Estimates

Strong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021 Positioned for Total Revenue and Net Income Growth in 2023   Xywav Enters 2023 as the Oxybate Therapy of Choice and Company's Largest Product by Net Sales Enhanced Investment in R&D to Advance Pipeline towards Key Value Inflection Points in 2023 and 2024 Company is Well-Positioned to Achieve Vision 2025 DUBLIN , March 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2022 and provided financial guidance for 2023. "2022 was a year of significant execution across our business that exemplified our purpose to innovate to transform the lives of patients and their families and advanced Jazz towards achieving Vision 2025.

Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)

Jazz (JAZZ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Jazz (JAZZ) Could Beat Earnings Estimates Again

Analysts Estimate Jazz Pharmaceuticals (JAZZ) to Report a Decline in Earnings: What to Look Out for

DUBLIN , Feb. 15, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2022 fourth quarter and full year financial results on Wednesday, March 1, 2023, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.

Jazz Pharmaceuticals to Report 2022 Fourth Quarter and Full Year Financial Results on March 1, 2023

These two stocks could grow like weeds in the next five years and beyond.

2 Cannabis Stocks That Could Make You Richer

Amplify Alternative Harvest ETF

Their shares may be down, but their sales are up.

3 Cannabis Stocks With Double-Digit Percentage Revenue Growth

Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.

News for Jazz Pharmaceuticals Stock (JAZZ)